<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/24/brokerages-expect-arrowhead-pharmaceuticals-inc-nasdaqarwr-will-post-quarterly-sales-of-36-97-million.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-24T21:41:15+00:00"/>
    <meta property="og:title" content="Brokerages Expect Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Will Post Quarterly Sales of $36.97 Million"/>
    <meta property="og:description" content="Analysts predict that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will announce $36.97 million in sales for the current quarter, according to Zacks. Four analysts have provided estimates for Arrowhead Pharmaceuticals’ earnings. The lowest sales estimate is $30.00 million and the highest is $45.00 million. Arrowhead Pharmaceuticals reported sales of $11.26 million during the same quarter last year, […]"/>
  </head>
  <body>
    <article>
      <h1>Brokerages Expect Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Will Post Quarterly Sales of $36.97 Million</h1>
      <address><time datetime="2019-11-24T21:41:15+00:00">24 Nov 2019, 21:41</time> by <a rel="author" href="https://www.thecerbatgem.com/author/amy" target="_blank">Amy Steele</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/arrowhead-pharmaceuticals-inc-logo.jpg"/>
      </figure>
      <p>Analysts predict that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will announce $36.97 million in sales for the current quarter, according to <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks</a>. Four analysts have provided estimates for Arrowhead Pharmaceuticals’ earnings. The lowest sales estimate is $30.00 million and the highest is $45.00 million. Arrowhead Pharmaceuticals reported sales of $11.26 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 228.3%. The firm is scheduled to report its next quarterly earnings results after the market closes on Monday, November 25th.</p>
      <p>According to Zacks, analysts expect that Arrowhead Pharmaceuticals will report full year sales of $166.73 million for the current year, with estimates ranging from $155.50 million to $180.50 million. For the next year, analysts forecast that the company will post sales of $77.87 million, with estimates ranging from $40.00 million to $129.00 million. Zacks’ sales calculations are an average based on a survey of research analysts that follow Arrowhead Pharmaceuticals.</p>
      <p>Several research firms have recently weighed in on ARWR. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=ARWR">ValuEngine</a> downgraded Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Cantor Fitzgerald reiterated a “neutral” rating and set a $50.00 target price (up from $24.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, November 19th. Piper Jaffray Companies lifted their target price on Arrowhead Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a research report on Sunday, October 20th. B. Riley lifted their target price on Arrowhead Pharmaceuticals from $46.00 to $59.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, Robert W. Baird downgraded Arrowhead Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $39.00 target price for the company. in a research report on Thursday, October 24th. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $49.40.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/ARWR/earnings/">Arrowhead Pharmaceuticals stock</a> traded up $0.14 during midday trading on Friday, hitting $49.20. The stock had a trading volume of 964,200 shares, compared to its average volume of 1,572,304. Arrowhead Pharmaceuticals has a 52-week low of $10.41 and a 52-week high of $51.84. The company has a market capitalization of $4.65 billion, a PE ratio of -75.69 and a beta of 1.68. The firm’s fifty day moving average is $39.13 and its two-hundred day moving average is $30.34.</p>
      <p>In other news, CFO Kenneth Allen Myszkowski sold 37,884 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $40.85, for a total transaction of $1,547,561.40. Following the transaction, the chief financial officer now owns 351,420 shares in the company, valued at $14,355,507. The sale was disclosed in a legal filing with the SEC, which is accessible through <a href="https://www.sec.gov/Archives/edgar/data/879407/000120919119054789/xslF345X03/doc4.xml">this link</a>. Also, CEO Christopher Richard Anzalone sold 4,250 shares of the firm’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $29.00, for a total value of $123,250.00. Following the transaction, the chief executive officer now owns 2,146,153 shares in the company, valued at approximately $62,238,437. The disclosure for this sale can be found <a href="https://www.sec.gov/Archives/edgar/data/879407/000120919119050606/xslF345X03/doc4.xml">here</a>. Over the last quarter, insiders have sold 350,104 shares of company stock valued at $10,783,025. Corporate insiders own 4.80% of the company’s stock.</p>
      <p>Institutional investors have recently made changes to their positions in the company. JPMorgan Chase &amp; Co. increased its stake in shares of Arrowhead Pharmaceuticals by 3.9% during the second quarter. JPMorgan Chase &amp; Co. now owns 315,152 shares of the biotechnology company’s stock valued at $9,083,000 after buying an additional 11,907 shares during the period. Aperio Group LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at $483,000. Comerica Bank purchased a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at $2,527,000. Elkfork Partners LLC increased its stake in shares of Arrowhead Pharmaceuticals by 467.6% during the second quarter. Elkfork Partners LLC now owns 13,124 shares of the biotechnology company’s stock valued at $348,000 after buying an additional 10,812 shares during the period. Finally, Parametric Portfolio Associates LLC increased its stake in shares of Arrowhead Pharmaceuticals by 60.1% during the second quarter. Parametric Portfolio Associates LLC now owns 80,302 shares of the biotechnology company’s stock valued at $2,128,000 after buying an additional 30,147 shares during the period. Hedge funds and other institutional investors own 72.30% of the company’s stock.</p>
      <p>
        <b>About Arrowhead Pharmaceuticals</b>
      </p>
      <p>Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.</p>
      <p>Featured Article: <a href="https://www.marketbeat.com/financial-terms/what-is-meant-by-holder-of-record/">What is meant by holder of record?</a></p>
      <p>
        <a href="https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&amp;ADID=AMERBMN_CONTENT_ZER&amp;skip_rpt_name_check=skip_rpt_name_check&amp;t=ARWR">Get a free copy of the Zacks research report on Arrowhead Pharmaceuticals (ARWR)</a>
      </p>
      <p>For more information about research offerings from Zacks Investment Research, visit <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks.com</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=ARWR"/>
      </figure>
    </article>
  </body>
</html>